Antitumor activity of recombinant oncolytic vaccinia virus with human IL2
Authors:
Open Access
- 1 January 2022
- journal article
- research article
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 17 (1) , 1084-1091
Abstract
The tumor microenvironment is highly immunosuppressive. The genetically modified oncolytic vaccinia virus (OVV) is a promising vector for cancer immunotherapy. The aim of the present study was to assess the antitumor effects of human interleukin-2 (hIL2)-armed OVV in vitro. The hIL2 gene was inserted into a thymidine kinase and the viral growth factor double deleted oncolytic VV (VVDD) to generate recombinant hIL2-armed OVV (rVVDD-hIL2). Viral replication capacity in A549 cells was quantified by plaque titration on CV-1 cells. Production of hIL2 in cancer cells infected by rVVDD-hIL2 was measured by enzyme-linked immunosorbent assay. Finally, 3-(4,5-dimethylthiazol-2-yl)-5-(3-arboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay was performed to assess the antitumor effects of rVVDD-hIL2. The results showed that rVVDD-hIL2 viral particles expressed increasing levels of hIL2 in human and murine cancer cell lines with growing multiplicities of infection (MOIs). The insertion of the hIL2 gene did not impair the replication capacity of VV, and the rVVDD-hIL2 virus killed cancer cells efficaciously. The lytic effects of the recombinant oncolytic virus on tumor cells increased with the growing MOIs. In conclusion, these findings suggest that hIL2-armed VVDD effectively infects and lyses tumor cells, with high expression of hIL2.Keywords
This publication has 41 references indexed in Scilit:
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerNature Medicine, 2013
- Phase II trial of hu14.18-IL2 for patients with metastatic melanomaCancer Immunology, Immunotherapy, 2012
- Cytokines in Cancer ImmunotherapyCancers, 2011
- Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II StudyJournal of Clinical Oncology, 2010
- Polarized dendritic cells as cancer vaccines: Directing effector-type T cells to tumorsSeminars in Immunology, 2010
- Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancerNature Reviews Cancer, 2009
- The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptorsArthritis Research & Therapy, 2007
- Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSFMolecular Therapy, 2006
- Effector Memory T Cells, Early Metastasis, and Survival in Colorectal CancerNew England Journal of Medicine, 2005
- Immunosuppressive networks in the tumour environment and their therapeutic relevanceNature Reviews Cancer, 2005